Modality
Small Molecule
MOA
EGFRi
Target
PLK4
Pathway
Cell Cycle
Pompe
Development Pipeline
Preclinical
Feb 2020
→ Mar 2028
PreclinicalCurrent
NCT08460077
1,961 pts·Pompe
2020-02→2028-03·Not yet recruiting
1,961 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-142.0y awayInterim· Pompe
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Not yet…
Catalysts
Interim
2028-03-14 · 2.0y away
Pompe
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08460077 | Preclinical | Pompe | Not yet recr... | 1961 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |